Pharvaris director sells 10,000 shares after option exercise
Pharvaris N.V. director Robert Glassman reported an exercise-and-sell transaction in company stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Pharvaris N.V. director Robert Glassman reported an exercise-and-sell transaction in company stock. On May 15, 2026, he exercised stock options for 5,333 shares of common stock at a price of $22.31 per share, then sold a total of 10,000 shares in open-market transactions at weighted average prices around $29.82 per share. The sales were executed in multiple trades within price ranges disclosed in the footnotes, and his directly held stake after the transactions was 10,500 common shares. The option exercised was fully vested as of April 11, 2025.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
4 txns
Insider
Glassman Robert
Role
Director
Sold
10,000 shs ($298K)
Approx. gross sale proceeds
$298K
Approx. exercise cost
$119K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 5,333 | $0.00 | $0.00 |
| Exercise | Common Stock | 5,333 | $22.31 | $119K |
| Sale | Common Stock | 5,333 | $29.8314 | $159K |
| Sale | Common Stock | 4,667 | $29.8167 | $139K |
Holdings After Transaction:
Stock Option (Right to Buy) — 8,667 contracts (Direct);
Common Stock — 10,500 shares (Direct)
Footnotes (3)
- F1. The reported price represents a weighted sale price for shares sold in multiple transactions on the reported date. The shares reported herein include shares of common stock acquired upon vestring of restricted stock units on various dates. The sales prices for the transactions ranged from $29.6550 to $29.92. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F2. The reported price represents a weighted sale price for shares sold in multiple transactions on the reported date. The shares reported herein include shares of common stock acquired upon vestring of restricted stock units on various dates. The sales prices for the transactions ranged from $29.7750 to $29.74. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- F3. 100% of the option vested on anniversary of grant, April 11th, 2025.
Key Figures
Shares sold: 10,000 shares
First sale price: $29.8167/share
Second sale price: $29.8314/share
+4 more
7 metrics
Shares sold
10,000 shares
Total common shares sold on May 15, 2026
First sale price
$29.8167/share
Weighted average price for 4,667 shares sold
Second sale price
$29.8314/share
Weighted average price for 5,333 shares sold
Options exercised
5,333 shares
Common stock acquired via option exercise
Exercise price
$22.31/share
Stock option exercise price on May 15, 2026
Shares held after
10,500 shares
Direct Pharvaris common stock ownership after transactions
Option expiration
April 11, 2034
Expiration date of the exercised stock option grant
Key Terms
open-market sale, derivative exercise/conversion, Stock Option (Right to Buy), weighted sale price, +1 more
5 terms
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative exercise/conversion financial
"transaction_action: derivative exercise/conversion"
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
weighted sale price financial
"The reported price represents a weighted sale price for shares sold"
restricted stock units financial
"shares of common stock acquired upon vestring of restricted stock units on various dates"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Pharvaris (PHVS) director Robert Glassman report in this Form 4?
Robert Glassman reported an exercise-and-sell transaction in Pharvaris common stock. He exercised stock options for 5,333 shares, then sold 10,000 shares in open-market trades, updating his directly owned position with the company’s shares.
What stock options did Robert Glassman exercise in this Pharvaris (PHVS) filing?
He exercised a stock option for 5,333 Pharvaris common shares at an exercise price of $22.31 per share. The option related to a grant that became fully vested on April 11, 2025, before the reported exercise and subsequent share sales.
Do the Pharvaris (PHVS) Form 4 footnotes mention restricted stock units for Robert Glassman?
Yes. The footnotes state that the reported shares include common stock previously acquired upon vesting of restricted stock units on various dates. This clarifies that part of Glassman’s holdings came from equity awards that had already vested before sale.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates